On August 3, Hims & Hers Health Inc. rose 5.01% in regular trading, trading at $29.97/share, with turnover of $65.27 million. The stock extended its recovery trajectory following the sharp selloff triggered by the FTC lawsuit on July 30.

The U.S. Federal Trade Commission filed suit against the company on July 30, alleging it shared users' health data with Meta Platforms and Snap without consent, and cited violations in billing practices and subscription cancellation policies. Shares initially plunged over 12% on the news. However, the company issued a forceful rebuttal, stating the allegations are baseless and that the FTC ignored substantial evidence submitted over nearly three years of investigation. The stock has since recovered from its intraday low of $24.24 on that day.

Market attention is also turning to the upcoming Q2 earnings release scheduled for August 10 after market close. Consensus estimates project revenue of approximately $700 million, representing 26.88% year-over-year growth, with adjusted EPS expected at -$0.01.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)